Seattle biotech company RareCyte raises $20M to accelerate product development

RareCyte, a Seattle-based biotech company, recently announced that it has raised $20 million from new and current investors. This funding boost is set to significantly expand RareCyte’s Orion platform for spatial biology, which allows researchers to view high-resolution molecules within cells or tissues.  

In a recent release, Joe Victor, CEO of RareCyte, stated, “This funding will allow RareCyte to accelerate the development of our broad menu of spatial biology assays, applications and software products to benefit our customers worldwide.” Victor, an experienced leader in life sciences, has been CEO of RareCyte since 2017.

With this recent funding milestone, RareCyte plans to revolutionize spatial biology through its enhanced Orion platform, creating efficient research methods and innovative treatments.

READ THE STORY at Puget Sound Business Journal »